Literature DB >> 7579375

Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after.

Catherine Pellat-Deceunynck, M Amiot, R Bataille, I Van Riet, B Van Camp, P Omede, M Boccadoro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7579375

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

1.  Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Authors:  Zhoumou Chen; Kali Janes; Collin Chen; Tim Doyle; Leesa Bryant; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

2.  Distinct isoform of FABP7 revealed by screening for retroelement-activated genes in diffuse large B-cell lymphoma.

Authors:  Frances E Lock; Rita Rebollo; Katharine Miceli-Royer; Liane Gagnier; Sabrina Kuah; Artem Babaian; Maialen Sistiaga-Poveda; C Benjamin Lai; Oksana Nemirovsky; Isabel Serrano; Christian Steidl; Mohammad M Karimi; Dixie L Mager
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

3.  A preclinical assay for chemosensitivity in multiple myeloma.

Authors:  Zayar P Khin; Maria L C Ribeiro; Timothy Jacobson; Lori Hazlehurst; Lia Perez; Rachid Baz; Kenneth Shain; Ariosto S Silva
Journal:  Cancer Res       Date:  2013-12-05       Impact factor: 12.701

4.  Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma.

Authors:  Q Chen; B Gong; A S Mahmoud-Ahmed; A Zhou; E D Hsi; M Hussein; A Almasan
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

5.  Use of transcriptional signatures induced in lymphoid and myeloid cell lines as an inflammatory biomarker in Type 1 diabetes.

Authors:  Shuang Jia; Mary Kaldunski; Parthav Jailwala; Rhonda Geoffrey; Joanna Kramer; Xujing Wang; Martin J Hessner
Journal:  Physiol Genomics       Date:  2011-03-15       Impact factor: 3.107

Review 6.  Persistent use of false myeloma cell lines.

Authors:  Hans G Drexler; Yoshinobu Matsuo; Roderick A E MacLeod
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

7.  BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.

Authors:  Chun Hei Antonio Cheung; Wen-Hsing Lin; John Tsu-An Hsu; Tzyh-Chyuan Hour; Teng-Kuang Yeh; Shengkai Ko; Tzu-Wen Lien; Mohane Selvaraj Coumar; Jin-Fen Liu; Wen-Yang Lai; Hui-Yi Shiao; Tian-Ren Lee; Hsing-Pang Hsieh; Jang-Yang Chang
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

8.  Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.

Authors:  Sylvia Feyler; Gina B Scott; Christopher Parrish; Sarah Jarmin; Paul Evans; Mike Short; Katherine McKinley; Peter J Selby; Gordon Cook
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

9.  Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse.

Authors:  K Vanderkerken; H De Raeve; E Goes; S Van Meirvenne; J Radl; I Van Riet; K Thielemans; B Van Camp
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.

Authors:  F Maura; M Petljak; M Lionetti; I Cifola; W Liang; E Pinatel; L B Alexandrov; A Fullam; I Martincorena; K J Dawson; N Angelopoulos; M K Samur; R Szalat; J Zamora; P Tarpey; H Davies; P Corradini; K C Anderson; S Minvielle; A Neri; H Avet-Loiseau; J Keats; P J Campbell; N C Munshi; N Bolli
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.